Sarah Cannon Research Institute

Sarah Cannon Research Institute

研究服务

Nashville,TN 15,248 位关注者

A leading oncology research organization conducting community-based clinical trials.

关于我们

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 750 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI’s research network brings together more than 1,300 physicians who are actively enrolling patients into clinical trials at more than 250 locations in 24 states across the U.S.

网站
https://www.scri.com
所属行业
研究服务
规模
501-1,000 人
总部
Nashville,TN
类型
私人持股
创立
1993
领域
Oncology和Cancer Research

地点

  • 主要

    1100 Charlotte Avenue

    US,TN,Nashville,37203

    获取路线

Sarah Cannon Research Institute员工

动态

  • 查看Sarah Cannon Research Institute的公司主页,图片

    15,248 位关注者

    Jeff Sharman M.D., Disease Chair; Lymphoma; Hematology Research Executive Committee at SCRI, is a leading expert in the latest advancements in lymphoma and a champion for patient-centered clinical trials. Explore his latest article to learn more about the breakthroughs in lymphoma treatment and our ongoing mission to advance the fight against blood cancer. #BloodCancerAwarenessMonth #Lymphoma #CancerResearch #ClinicalTrials #SCRI

    查看Jeff Sharman M.D.的档案,图片

    Medical director of hematology research for US Oncology. Clinical thought leader in drug development; providing strategic guidance to biotech, pharma, and capital creators advancing novel cancer therapeutics

    As we recognize #BloodCancerAwarenessMonth, I'm reflecting on the incredible progress we've made in lymphoma research, and the lives we've touched through our work locally Willamette Valley Cancer Institute & Research Center in collaboration with Sarah Cannon Research Institute and The US Oncology Network. From cutting-edge clinical trials to groundbreaking treatments, we're bringing hope closer for countless patients.

    Advancements in Lymphoma: The Power of Patient-Centric Research

    Advancements in Lymphoma: The Power of Patient-Centric Research

    Jeff Sharman M.D.,发布于领英

  • 查看Sarah Cannon Research Institute的公司主页,图片

    15,248 位关注者

    At SCRI, patients are central to everything we do! Colleague Les Rutt has witnessed how our Contract Research Organization (CRO) arm puts this commitment to our mission into practice, first-hand. It’s this reason that Les decided to return to SCRI to work with our team after time at another organization. ? Learn more about our cultural commitments that drive our dedicated colleagues: https://lnkd.in/e5hFN2ri

    • 该图片无替代文字
  • 查看Sarah Cannon Research Institute的公司主页,图片

    15,248 位关注者

    “Participation in clinical trials should be the first step in fighting cancer, not the last.” – Skip Burris, MD, President, Sarah Cannon Research Institute (SCRI).? These words ring especially true for SCRI patient, Jim, who in April of 2024 was diagnosed with stage IV metastatic prostate cancer. In July 2024, after enrolling immediately on a clinical trial, scans showed little sign of disease. Jim, a 20-year healthcare executive from Nashville, Tenn., had kept an eye on a nagging high prostate-specific antigen (PSA) score that recurred within his bloodwork. He and his primary care physician carefully watched the numbers and then within four months, the number tripled. A blood PSA score can indicate higher risk for prostate cancer and, ultimately in Jim’s case, indicted cancer. Jim immediately reached out to Sarah Cannon Research Institute (SCRI) to determine his options.? Jim began care with Benjamin Garmezy, MD, Associate Director, Genitourinary Cancer Research, SCRI and Medical Oncologist, SCRI Oncology Partners who ordered additional testing and scans. These revealed stage IV metastatic prostate cancer with spread to lymph nodes, hips and spine.? “I was absolutely terrified. I didn’t know what to think and it’s still difficult to put into words what it is like to hear the word ‘cancer’,” Jim said. “You never think it is going to happen to you. Then when it does, you are paralyzed.” Dr. Garmezy suggested an aggressive treatment – first by controlling his testosterone levels, which can fuel prostate cancer, followed by enrollment in a clinical trial aimed to target his type of cancer.? “I am very competitive, type-A personality and a fighter, but you can’t fight something that is internal by yourself. I was reeling from the diagnosis and needed someone to help me make a plan. Dr. Garmezy helped me get off the mat. With that first treatment, I felt like I was doing something to combat the cancer, I could finally fight. With a plan, I felt optimistic.” Jim enrolled on a clinical trial to intensify his hormonal treatment which includes two daily oral medications and an injection every few months with very little side effects. “I was afraid I would have to trade my vitality to get better. I haven’t - which is amazing. I do have fatigue and a little GI upset but I’ve been able to work and vacation during my battle. I’m just so thankful to maintain quality of life.” Within three months, Jim’s scans revealed that his cancer is nearly gone. His PSA score went from almost 80 and is now undetectable (a low level is under 4).? “This clinical trial has been a miracle for me and saved my life. I have so much life left to live. I was so fearful this was a death sentence. The people at SCRI have been so amazing to not only me, but to my caretaker as well.”? Jim will remain on the clinical trial as long as it continues to be effective. For Jim, a clinical trial was his first step in fighting cancer and has proven to be successful.?

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
  • 查看Sarah Cannon Research Institute的公司主页,图片

    15,248 位关注者

    Today, on World Cancer Research Day, Sarah Cannon Research Institute proudly reflects on our work to advance cancer treatment through research and innovation. ?? With more than 1,000 trials actively enrolling, our commitment to advancing cancer therapies for patients is at the center of everything we do. Our team of over 1,300 dedicated research physicians works tirelessly to bring new hope to patients and their families. ?? We are honored to have participated in the development of the majority of FDA-approved cancer therapies available. ???? With 750+ first-in-human trials conducted at SCRI, we aim to make the latest cutting-edge therapies accessible to patients across the U.S. ?? Each year, we register more than 4,500 patients to enroll in our trials, providing access to treatments for patients, closer to home. Together, we are making strides in the fight against cancer. Thank you for your continued support and partnership in our mission to bring hope and healing to those affected by this disease. #WorldCancerResearchDay #CancerResearch #SCRI

  • Sarah Cannon Research Institute转发了

    查看Vivek Subbiah, MD的档案,图片

    Chief, Early-Phase Drug Development, Sarah Cannon Research Institute

    ??Bright and early?? ??Just recorded a LIVE NEWS segment on cutting-edge oncology progress ????team tagging with world-renowned breast cancer expert Dr. Erika Hamilton Erika Hamilton, MD for NewsNation ????Stay tuned for the link #DynamicDuo Sarah Cannon Research Institute SCRI Oncology Partners #Oncology #PrecisionOncology #Personalizedmedicine #tissueagnostic drugs #BreastCancer OncoAlert

    • 该图片无替代文字
  • 查看Sarah Cannon Research Institute的公司主页,图片

    15,248 位关注者

    Dr. Anderson, Executive Member, Gynecologic Cancer Research Executive Committee, SCRI at Willamette Valley Cancer Institute & Research Center, believes we’ve entered the “Golden Era” of ovarian cancer research. With so many exciting advancements happening over the last two years, he’s never been more optimistic about the future for individuals impacted by ovarian cancer. Read more as he reflects on the latest clinical trials and research taking place and what he’s most looking forward to in recognition of Ovarian Cancer Awareness Month. #OvarianCancerAwareness #CancerResearch #ClinicalTrials #OvarianCancer #PatientCare #SCRI

    The Power of Early Intervention: Transforming Outcomes in Gynecological Cancer

    The Power of Early Intervention: Transforming Outcomes in Gynecological Cancer

    Sarah Cannon Research Institute,发布于领英

  • 查看Sarah Cannon Research Institute的公司主页,图片

    15,248 位关注者

    Clinical trials are essential for advancing cancer therapies. Participating in a trial ensures rigorous safety, offers access to the latest treatments, and contributes to future cancer care. SCRI expert, Vivek Subbiah, MD, debunks myths surrounding clinical trials and highlights the importance of exploring this option in the article below.

    查看Vivek Subbiah, MD的档案,图片

    Chief, Early-Phase Drug Development, Sarah Cannon Research Institute

    ? ?? The importance of clinical trials cannot be overstated. ?? They are the foundation to advancing patient care in oncology. Yet, there is a growing need for patient enrollment which can be affected by a multitude of factors such as education, awareness, and access. ?? Learn about some of the common misconceptions associated with cancer clinical trials below. #ClinicalTrials #Oncology #CancerResearch #CancerClinicalTrials Sarah Cannon Research Institute

    Clinical Trial Fact v. Fiction

    Clinical Trial Fact v. Fiction

    Vivek Subbiah, MD,发布于领英

  • 查看Sarah Cannon Research Institute的公司主页,图片

    15,248 位关注者

    SCRI and Florida Cancer Specialists & Research Institute work together to bring cutting-edge therapies to patients throughout Florida. We are excited about the opportunities this integration will have for our continued research operations with FCS. #CancerResearch

    查看McKesson的公司主页,图片

    483,733 位关注者

    Today we announced a definitive agreement to acquire a controlling interest in Core Ventures, a business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading community oncology practice. Following the close of the transaction, FCS, a practice with more than 250 physicians and 280 advanced practice providers across nearly 100 locations in Florida, will remain independently owned, and FCS will join McKesson’s The US Oncology Network, a leading oncology organization dedicated to advancing local and affordable cancer care and better patient outcomes. Learn more: https://lnkd.in/g5rFwFAP

  • 查看Sarah Cannon Research Institute的公司主页,图片

    15,248 位关注者

    Are you new to the corporate environment and eager to enhance your communication skills? , Join us on August 12 for a session on mastering professional communication for newcomers. Monday's seeSCRI (Student Early Exposure) session is essential for students seeking career advice. Attendees will benefit from insights shared by Rebecca Hill, our HR Director. Register today or share this opportunity with students interested in professional development and career planning. Register here: https://lnkd.in/eqw2Yxj2 #CorporateCoaching #CareerEducation #CorporateCommunication

  • 查看Sarah Cannon Research Institute的公司主页,图片

    15,248 位关注者

    Get off to a smooth start! Join us on August 8 to learn how to navigate the transition from college to the workplace.? ? Register now: https://lnkd.in/eqw2Yxj2 Tomorrow's seeSCRI (Student Early Exposure) session is essential for any student seeking career guidance. Attendees will hear from our Vice President of HR, Amanda K. Belcher, M.A.. Register now or share this opportunity with a student eager for professional development and career planning advice. #careerplanning #studentseminar #clinicaloncology

关联主页

相似主页

查看职位